Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2002

View Archived Issues

Drug pipeline for sleep disorders

Several related series of antidepressants under development at Wyeth

Celltech presents novel receptor tyrosine kinase inhibitors for cancer, psoriasis, etc.

Aventis claims CDK2 inhibitors for cancer and chemotherapy-induced neuronal apoptosis

Novel glucocorticoids in early development at GSK

Aventis discovers antiarrhythmic Kv1.5 channel blockers

New inhibitors of fatty acid amide hydrolase with utility in neuropathic pain

Vertex describes the preparation and use of novel beta-secretase inhibitors

Promising toxicity and antitumor efficacy for temozolomide + vatalanib succinate in glioblastoma

Potential use of TP-38 in recurrent malignant brain tumors

Improved survival rate found with 131I-ch81C6 in malignant brain tumors

SU-11248: preclinical and early clinical findings encourage further development

Telomerase inhibitor with potential as an antitumor and radiosensitizing agent

Sulfonyhydrazine prodrug VNP-40101M advances towards phase II clinical evaluation

Corixa withdraws dispute resolution as FDA returns Bexxar to active review status

Human Genome Sciences and Kirin announce license agreement

Taxotere approved for first-line therapy in NSCLC

Lexapro oral solution provides new option for depressed patients

Approvable letter for Pennsaid in Canada

Axcan receives approvable letter for Photofrin

Enrollment completed in phase III trial of ABI-007

Genetronics and Chiron extend collaboration to test HIV vaccine delivery

Mercury Therapeutics licenses oncology target from Mass General

Milestone reached in Mercury Therapeutics and Aventis AMPK collaboration

Antibody product enters phase I for autoimmune disease

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...